A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants

This is a single-center, open-label (identity of study drug will be known to participant and
study staff), single-dose, parallel-group study. The study consist of Screening Phase (Days
-21 to -2), Open-label treatment Phase (Day -1 up to Day 8) and End of Study (9 to 13 days
after last study assessment). The total duration of study from the Screening Phase through
Follow-up, is 37-41 days. Participants will be assigned to 1 of the two groups (Cohort 1 and
Cohort 2) during the treatment phase. The participants will be primarily evaluated to
determine the metabolic disposition of radiolabeled esketamine administered by the oral and
intravenous routes. Participants' safety will be monitored throughout the study.

Inclusion Criteria:

- Participants willing to adhere to the prohibitions and restrictions specified in the
protocol

- If a man who is sexually active with a woman of child-bearing potential and has not
had a vasectomy, must agree to use an adequate contraception method as deemed
appropriate by the investigator (example, vasectomy, double-barrier, partner using
effective contraception) for 3 months following administration of study drug

- Participants with body mass index (BMI) between 18 and 30 kilogram per square meter
(kg/m^2) (inclusive), and body weight not less than 50 kg

- Blood pressure (after the participant is supine for 5 minutes) between 90 and 140
millimeter of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg
diastolic. Note: Average from 3 supine measurements will be used at screening visit

- A 12-lead electrocardiogram (ECG) consistent with normal cardiac conduction and
function, including: Sinus rhythm; Heart rate between 45 and 90 beats per minute
(bpm); QTc interval less than or equal to (<=)450 milliseconds (ms); QRS interval of
<110 ms; PR interval <200 ms; Morphology consistent with healthy cardiac conduction
and function

Exclusion Criteria:

- Participants diagnosed with a current or previous psychiatric or bipolar disorder, as
assessed by the investigator, will not be permitted to participate in the study

- Current suicidal or homicidal ideation/intent/behavior as assessed by Columbia
Suicide Severity Rating Scale (C-SSRS) at screening

- Clinically significant abnormal values for hematology, clinical chemistry or
urinalysis at screening or at admission to the study center on Day -1 as deemed
appropriate by the investigator

- Clinically significant abnormal physical examination, vital signs or 12-lead ECG at
screening or Day -1, and as deemed appropriate by the investigator

- Use of any prescription or nonprescription medication (including vitamins and herbal
supplements) within 14 days before study drug administration is scheduled, except for
acetaminophen